CD4(+), CD56(+) DC2 acute leukemia is characterized by recurrent clonal chromosomal changes affecting 6 major targets: a study of 21 cases by the Groupe Français de Cytogénétique Hématologique.

@article{Leroux2002CD4CD,
  title={CD4(+), CD56(+) DC2 acute leukemia is characterized by recurrent clonal chromosomal changes affecting 6 major targets: a study of 21 cases by the Groupe Français de Cytog{\'e}n{\'e}tique H{\'e}matologique.},
  author={Dominique Leroux and Francine Mugneret and Mary Callanan and Isabelle Radford-weiss and Nicole Dastugue and Jean Feuillard and Franseza Le M{\'e}e and Ghislaine Plessis and Pascaline Talmant and Nathalie Gachard and Françoise Uettwiller and Marie-Pierre Pag{\`e}s and M J Mozziconacci and Virginie Eclache and Catherine Sibille and Herv{\'e} Avet-Loiseau and Marina Lafage-Pochitaloff},
  journal={Blood},
  year={2002},
  volume={99 11},
  pages={4154-9}
}
CD4(+), CD56(+) DC2 malignancies constitute a novel disease entity, which has recently been shown to arise from a transformed lymphoid-related plasmacytoid dendritic cell (DC2). Diagnosis is primarily based on a particular immunophenotype with tumor cells expressing CD4 and CD56 antigens in the absence of common lymphoid or myeloid lineage markers. Little is currently known about the cytogenetic features of this disease entity. In this setting, the Groupe Français de Cytogénétique Hématologique… CONTINUE READING